The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-
modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding …

Multiple Sclerosis (MS) is a chronic neurodegenerative autoimmune disorder of the central
nervous system (CNS) and the most common cause of serious physical disability in working …

In the recent past, a plethora of drugs have been approved for the treatment of multiple
sclerosis (MS). These therapeutics are mainly confined to immunomodulatory or …

In recent years, multiple sclerosis (MS) research has progressed on several fronts,
prompting numerous clinical trials, primarily for immunotherapeutics. Although several new …

Remyelination in the CNS is the natural process of damage repair in demyelinating
diseases such as multiple sclerosis (MS). However, remyelination becomes inadequate in …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
characterized by demyelination and axonal degeneration. MS patients typically present with …

Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune disease of
the central nervous system (CNS). Disease-modifying therapies (DMT) targeting …

Several disease‐modifying drugs (DMDs) are currently approved for the treatment of
multiple sclerosis (MS). Recently, there has been increased identification and development …

Multiple sclerosis (MS), an incurable but manageable disorder, is characterized by chronic
inflammatory demyelination and neurodegeneration in the central nervous system. Although …

Although the cause of multiple sclerosis (MS) has remained obscure, many findings support
an autoimmune pathogenesis on the background of a complex interaction between multiple …